Revenue Growth
Revenue for Q3 2024 was $489.6 million, up 3.3% year-over-year from $474.0 million in Q3 2023.
Adjusted EBITDA Increase
Adjusted EBITDA grew by 2.7% to $101.6 million in Q3 2024 compared to $98.9 million in Q3 2023.
Expansion of Locations
Concentra added 21 more locations, totaling 705, compared to the end of Q3 2023.
Cash Flow and Leverage Improvement
Operating activities generated $65.9 million in cash flow, with the net leverage ratio improving from 3.9x at IPO to 3.7x at September 30, 2024.
Dividend Announcement
Concentra's Board declared a cash dividend of $0.0625 per share, payable on November 22, 2024.
New Business Development
More than 10 new on-site health clinics, including advanced primary care services, are set to open in the coming months.